Drug Candidates in Retinitis Pigmentosa Therapeutics

Retinitis Pigmentosa Therapeutics
Insights on market segments
Orphan drug designations from the regulatory bodies such as Food and
Drug Administration (FDA), European Medicines Agency (EMA) and Ministry
of Health, Labour and Welfare (MHLW) is a key driver for the development
of pipeline drugs, for treating retinitis pigmentosa. Majority of the pipeline
drug candidates are being developed using the intravitreal route of
administration. HORAMA S.A. is in the process of developing two phase I/II,
and one Pre-Clinical therapeutics for the treatment of retinitis pigmentosa.